[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 17, 1997

Bioequivalence of Levothyroxine Preparations: Issues of Science, Publication, and Advertising

Author Affiliations

Oregon Health Sciences University Portland

JAMA. 1997;278(11):896-897. doi:10.1001/jama.1997.03550110034021
Abstract

To the Editor.  —The article by Dr Dong and colleagues1 highlights the nature of the problem of scientists' withholding data from colleagues and from peer-reviewed journals; Dr Rennie's Editorial2 touches on the possible sequelae of such limitations on the free exchange of scientific information involving pharmaceutical and biotechnology-related research. I am concerned about similar problems limiting the nature, scope, and dissemination of results in health services research.With the increasing enrollment of patients in managed care organizations (MCOs), coupled with cuts in government funding of organizations concerned with studying the processes and clinical outcomes of various models of clinical care for different diseases, more and more MCOs are funding internal outcome studies. Ideally, the goals of such research should be to study the effects of different clinical interventions on morbidity, mortality, and quality of life and to develop protocols for achieving enhanced outcomes at reduced cost. However, these organizations are increasingly

×